EUVIMEDEUVIMED entdecken
Klinische StudieOpen Access

RESET-PKD: a pilot trial on short-term ketogenic interventions in autosomal dominant polycystic kidney disease

Simon Oehm, Konstantin Steinke, Johannes Schmidt, Sita Arjune, Polina Todorova iD, Christoph Heinrich Lindemann, Fabian Wöstmann, Franziska Meyer, Florian Siedek, Thomas Weimbs iD, Roman-Ulrich Müller iD, Franziska Grundmann iD

Nephrology Dialysis Transplantation · 2023

DOI: 10.1093/ndt/gfac311 ↗

Kurz gefasst

Klinische Studie in der Zeitschrift Nephrology Dialysis Transplantation, 2023. Verfasst von Simon Oehm und 11 weiteren Autor:innen. Beteiligte Einrichtung: University of Cologne, Faculty of Medicine and University Hospital, Department 2 of Internal Medicine and Center for Molecular Medicine, Cologne, Ger…. Hauptthemen laut MEDLINE: Polycystic Kidney Diseases, Polycystic Kidney, Autosomal Dominant. Die Arbeit wurde bisher 43-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS, Koeln Fortune Program, Ministry of Science North Rhine-Westphalia.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Ketogenic dietary interventions (KDI) have been shown to be effective in animal models of polycystic kidney disease (PKD), but data from clinical trials are lacking.

Methods

Ten autosomal dominant PKD (ADPKD) patients with rapid disease progression were enrolled at visit V1 and initially maintained a carbohydrate-rich diet. At V2, patients entered one of the two KDI arms: a 3-day water fast (WF) or a 14-day ketogenic diet (KD). At V3, they resumed their normal diet for 3–6 weeks until V4. At each visit, magnetic resonance imaging kidney and liver volumetry was performed. Ketone bodies were evaluated to assess metabolic efficacy and questionnaires were used to determine feasibility.

Results

All participants [KD n = 5, WF n = 5; age 39.8 ± 11.6 years; estimated glomerular filtration rate 82 ± 23.5 mL/min/1.73 m2; total kidney volume (TKV) 2224 ± 1156 mL] were classified as Mayo Class 1C–1E. Acetone levels in breath and beta-hydroxybutyrate (BHB) blood levels increased in both study arms (V1 to V2 average acetone: 2.7 ± 1.2 p.p.m., V2 to V3: 22.8 ± 11.9 p.p.m., P = .0006; V1 to V2 average BHB: 0.22 ± 0.08 mmol/L, V2 to V3: 1.88 ± 0.93 mmol/L, P = .0008). Nine of 10 patients reached a ketogenic state and 9/10 evaluated KDIs as feasible. TKV did not change during this trial. However, we found a significant impact on total liver volume (ΔTLV V2 to V3: −7.7%, P = .01), mediated by changes in its non-cystic fraction.

Conclusions

RESET-PKD demonstrates that short-term KDIs potently induce ketogenesis and are feasible for ADPKD patients in daily life. While TLV quickly changed upon the onset of ketogenesis, changes in TKV may require longer-term interventions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Polycystic Kidney DiseasesPolycystic Kidney, Autosomal Dominant3-Hydroxybutyric AcidAcetoneDisease ProgressionGlomerular Filtration RateKidneyPilot ProjectsHumansAdultMiddle Aged

Stichwörter der Autor:innen

ADPKDfastingketogenic dietketosisnutritionpolycystic kidney disease

Substanzen

3-Hydroxybutyric AcidAcetone

Autor:innen und Institutionen

  • University of Cologne, Faculty of Medicine and University Hospital, Department 2 of Internal Medicine and Center for Molecular Medicine, Cologne, Germany.
  • University of Cologne, Faculty of Medicine and University Hospital, Institute of Diagnostic and Interventional Radiology, Cologne, Germany.
  • Department of Molecular, Cellular and Developmental Biology and Neuroscience Research Institute, University of California Santa Barbara, Santa Barbara, CA, USA.
  • Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany.

ORCID-Profile: Polina Todorova, Thomas Weimbs, Roman-Ulrich Müller, Franziska Grundmann

Förderung

  • NIDDK NIH HHS
  • Koeln Fortune Program
  • Ministry of Science North Rhine-Westphalia
  • DFG
  • NIH

Zitieren

APA

Oehm, S., Steinke, K., Schmidt, J., Arjune, S., Todorova, P., Heinrich Lindemann, C., Wöstmann, F., Meyer, F., Siedek, F., Weimbs, T., Müller, R. U., & Grundmann, F. (2023). RESET-PKD: a pilot trial on short-term ketogenic interventions in autosomal dominant polycystic kidney disease. Nephrology Dialysis Transplantation. https://doi.org/10.1093/ndt/gfac311

Vancouver

Oehm S, Steinke K, Schmidt J, Arjune S, Todorova P, Heinrich Lindemann C, et al. RESET-PKD: a pilot trial on short-term ketogenic interventions in autosomal dominant polycystic kidney disease. Nephrology Dialysis Transplantation. 2023. doi:10.1093/ndt/gfac311

BibTeX
@article{Oehm2023,
  author = {Oehm, Simon and Steinke, Konstantin and Schmidt, Johannes and Arjune, Sita and Todorova, Polina and Heinrich Lindemann, Christoph and Wöstmann, Fabian and Meyer, Franziska and Siedek, Florian and Weimbs, Thomas and Müller, Roman-Ulrich and Grundmann, Franziska},
  title = {RESET-PKD: a pilot trial on short-term ketogenic interventions in autosomal dominant polycystic kidney disease},
  journal = {Nephrology Dialysis Transplantation},
  year = {2023},
  doi = {10.1093/ndt/gfac311}
}
Kostenlos starten →